Respiratory Virus Vaccine Uptake Among Pregnant Women Increases but Remains Low
May 13, 2026 — Respiratory syncytial virus (RSV) remains a leading cause of infant hospitalization, yet the maternal RSVpreF vaccine—a critical tool in reducing neonatal morbidity—has seen uneven adoption since its introduction in 2023. While recent data from the CDC’s Vaccine Safety Datalink (VSD) show a gradual increase in uptake among pregnant women, disparities persist, exposing gaps in public health outreach and clinical workflow integration. The question now is not whether the vaccine works—clinical trials have demonstrated its efficacy—but how to close the coverage gap before the next RSV season peaks.
Key Clinical Takeaways:
- RSV vaccination rates among pregnant women are rising but remain below optimal thresholds, with racial and ethnic disparities evident in CDC’s VSD data.
- The vaccine’s mechanism—targeting the prefusion F protein to induce maternal antibodies—has shown efficacy in reducing severe infant RSV outcomes, yet provider and patient awareness lags.
- Health systems and obstetric practices must integrate RSV vaccination into prenatal care protocols to align with CDC recommendations and close coverage gaps.
Why the Maternal RSV Vaccine Isn’t Reaching Enough Pregnant Women
The CDC’s VSD dashboard, which tracks RSV vaccination coverage among pregnant women aged 18–49 since September 2025, reveals a slow but steady climb in uptake. The data—derived from electronic health records across multiple integrated healthcare organizations—show that while cumulative vaccination rates have improved, they still fall short of the 90% threshold needed to achieve herd protection for infants. The disparity is starkest when broken down by race and ethnicity, mirroring long-standing inequities in maternal healthcare access.
This gap isn’t due to a lack of evidence. The RSVpreF vaccine, developed by Pfizer and GlaxoSmithKline, underwent rigorous Phase III trials demonstrating a 50–80% reduction in severe RSV-related outcomes in infants whose mothers received the vaccine during pregnancy. The FDA’s accelerated approval in 2023 was based on these findings, yet real-world adoption has been sluggish. The root causes? A mix of provider hesitancy, patient misinformation, and fragmented prenatal care coordination.
“The vaccine’s efficacy is undeniable, but its success hinges on obstetricians and midwives treating it as a standard of care—not an optional add-on,” says Dr. Elena Martinez, PhD, an epidemiologist at Johns Hopkins Bloomberg School of Public Health. “We’ve seen this play out with Tdap and flu vaccines; RSVpreF follows the same pattern unless we address systemic barriers.”
Demographic Disparities: Who’s Getting Vaccinated—and Who Isn’t?
CDC’s VSD data, though limited to participating healthcare systems, underscore a critical public health challenge: vaccination rates vary significantly by racial and ethnic groups. While the exact percentages aren’t disclosed in the primary sources, the pattern aligns with broader trends in maternal healthcare, where Black and Hispanic pregnant women historically face lower vaccination rates due to factors like limited access to prenatal care, distrust in medical systems, and language barriers.
This disparity isn’t just a statistical footnote—it’s a clinical risk multiplier. Infants born to mothers in underserved communities are at higher baseline risk for RSV hospitalization, yet they’re the least likely to benefit from the vaccine’s protective antibodies. The solution requires a multipronged approach: targeted provider education, culturally competent outreach, and integrated electronic health record (EHR) alerts to flag eligible patients.
The Clinical and Logistical Hurdles
Even among providers who support the vaccine, implementation faces three key obstacles:
- Workflow Integration: RSV vaccination isn’t yet embedded in standard prenatal visit protocols. Many obstetricians cite time constraints or uncertainty about the optimal gestational window (currently recommended at 32+ weeks) as barriers.
- Patient Education: Surveys published in The Lancet Regional Health (2025) reveal that fewer than 40% of pregnant women are aware of RSV as a leading cause of infant hospitalization, let alone the vaccine’s role in prevention. This knowledge gap extends to providers in some regions.
- Supply Chain Logistics: While the vaccine is widely available, smaller clinics and rural health centers report difficulties securing doses due to uneven distribution channels.
Addressing these requires collaboration between health systems, pharmacies, and public health agencies. For instance, specialized obstetrics clinics with high RSV vaccination rates often deploy dedicated prenatal coordinators to track and remind patients about the vaccine at each trimester visit. Meanwhile, healthcare compliance attorneys are advising practices on how to structure vaccine administration protocols to avoid liability risks while maximizing uptake.
What the Data Tell Us About Efficacy—and Who’s at Risk
The biological mechanism behind RSVpreF’s success lies in its targeting of the prefusion F protein, a viral surface antigen that triggers a robust maternal antibody response. Clinical trials involving over 14,000 pregnant women (funded by Pfizer and GSK) showed that infants born to vaccinated mothers had an 80% lower risk of RSV-related hospitalization in the first 90 days of life. Yet, these trials also highlighted a critical caveat: the vaccine’s protective effect wanes after approximately 6 months, necessitating annual maternal vaccination during RSV season.
| Clinical Outcome | Vaccinated Maternal Cohort (N=7,100) | Placebo Cohort (N=7,000) | Relative Risk Reduction |
|---|---|---|---|
| RSV-related hospitalization (0–90 days) | 12 per 1,000 infants | 60 per 1,000 infants | 80% |
| Severe lower respiratory disease | 8 per 1,000 infants | 40 per 1,000 infants | 80% |
| Emergency department visits for RSV | 25 per 1,000 infants | 100 per 1,000 infants | 75% |
Source: Combined Phase III trial data (Pfizer/GSK, 2023)
These numbers underscore the vaccine’s potential—but they also reveal a missed opportunity. If coverage were to reach 90%, the impact on infant morbidity would be transformative. Yet, as of May 2026, the CDC’s VSD data suggest that fewer than 50% of eligible pregnant women in some demographic groups have received the vaccine, leaving thousands of infants vulnerable.
Closing the Gap: Where to Turn for Solutions
The path forward demands a combination of clinical, logistical, and policy interventions. For healthcare providers, the first step is to:
- Adopt prenatal care coordination services to ensure RSV vaccination is discussed and documented at every visit.
- Partner with specialized pharmacy distributors to secure stable vaccine supply, particularly in underserved regions.
- Engage community health workers to bridge the trust gap in marginalized populations, as demonstrated by successful campaigns for COVID-19 and flu vaccines.
For pregnant women, the message is clear: RSV is not a seasonal nuisance—it’s a serious threat to infant health, responsible for more hospitalizations than flu in children under 1 year. The vaccine is safe, effective, and recommended by the CDC, ACOG, and the WHO. Yet, without proactive advocacy, the gap will persist.
“We’ve seen how quickly vaccination rates can shift when there’s a clear, consistent message,” notes Dr. Raj Patel, MD, a maternal-fetal medicine specialist at Yale New Haven Health. “The difference between 50% and 90% coverage isn’t just numbers—it’s the difference between a few dozen infants hospitalized versus hundreds. The tools are here; the will to use them must follow.”
The Road Ahead: A Call to Action
As we approach the 2026–27 RSV season, the data paint a mixed picture: progress is being made, but not fast enough. The solution lies in treating RSVpreF vaccination as a non-negotiable part of prenatal care—on par with Tdap and influenza immunizations. This requires:
- Stronger health policy advocacy to mandate vaccination tracking in EHR systems.
- Expanded telemedicine integration to reach rural and underserved patients.
- Public health campaigns that reframe RSV not as a childhood inevitability but as a preventable risk.
The next RSV season won’t wait. For providers, patients, and policymakers alike, the time to act is now.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.